Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the EGFR gene, which are typically associated with a poorer prognosis (as compared to “classical” EGFR mutants causing NSCLC) and are associated with resistance to standard targeted EGFR inhibitors. Mobocertinib appears to be an effective means of treating this otherwise treatment-resistant NSCLC, exerting an inhibitory effect on EGFR exon 20 insertion mutant variants at concentrations 1.5- to 10-fold lower than those required to inhibit wild-type EGFR. Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic NSCLC in patients with EGFR exon 20 insertion mutations who have failed previous therapies. It is grouped under the following drug class(es): Tyrosine Kinase Inhibitors. Its therapeutic use is listed as anti-cancer agents. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Mobosetinib and AP32788. Its PubChem CID is 118607832.
Mobocertinib
| CAS No | 1847461-43-1 |
|---|---|
| Molecular Formula | C32H39N7O4 |
| Molecular Weight | 585.70 g/mol |
| Synonyms | propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR).
The listed CAS number is 1847461-43-1.
The listed molecular formula is C32H39N7O4.
The listed molecular weight is 585.70 g/mol.
propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate.
The source lists Mobosetinib and AP32788.